Mallinckrodt plc (MNK) topped market expectations on revenue and earnings for the fourth quarter of 2018, sending the shares soaring 12.9% in premarket hours on Tuesday.
Net sales grew 5.4% to $834.9 million from the same period last year. On a constant-currency basis, sales growth was 5.6%.
On a GAAP basis, the company reported a net loss of $3.7 billion, or $44.64 per share, compared to a net income of $1.6 billion, or $17.41 per share, in the prior-year period, mainly due to a non-cash goodwill impairment charge. Adjusted EPS improved 8.5% year-over-year to $2.18.
Mallinckrodt stated that the Specialty Generics Disposal Group, which was previously classified in discontinued operations, has been recast to continuing operations and the company now operates two reportable segments – the Specialty Brands segment and the Specialty Generics and Amitiza segment.
During the quarter, sales in the Specialty Brands segment totaled $586.5 million. INOMAX and OFIRMEV posted sales increases of 10.4% and 11.8% respectively, helped by strong demand and execution.
Net sales for HP Acthar Gel dropped 4.1% as the brand continues to tackle patient withdrawal issues and growing payer scrutiny on overall specialty pharmaceutical spending. Therakos net sales dipped slightly to $57 million in the quarter.
Also see: Mallinckrodt Q4 2018 Earnings Conference Call Transcript
In the Specialty Generics and Amitiza segment, net sales grew 23.8% to $248.4 million, mainly due to the inclusion of AMITIZA in early 2018. Excluding AMITIZA, net sales of the other Specialty Generics products dropped 8.4%. Mallinckrodt expects these declines to moderate and the segment to return to growth in 2019.
For the full year of 2019, Mallinckrodt expects adjusted EPS of $8.10 to $8.40. Total net sales for both the Specialty Brands and Specialty Generics and Amitiza segments are expected to increase 1-4%.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to